Adrenocortical carcinoma is a rare cancer with a poor survival rate. Mitotane is the main active systemic therapy in the advanced and adjuvant setting.
Improved outcomes have been demonstrated in patients who reach a plasma concentration between 14 and 20 mg/L.
However, its pharmacodynamics are highly variable, with up to 5-10 fold inter-patient variability. Drug level monitoring is essential to minimise toxicity and optimise patient outcomes.
The Calvary Mater Newcastle Hospital is the only site in Australia to offer mitotane plasma level monitoring. The Australian Rare Cancer Portal is working with their clinicians and researchers to help improve access to this service and collect treatment and outcome data for patients with adrenocortical carcinomas.
If you have a patient with an adrenal cancer of any stage, please consider referring them via the ARC Portal, to help contribute towards improving evidence for this rare cancer.
Refer a patient